Loading...

APC/Cyanine7 anti-mouse CD3 Antibody

Pricing & Availability
Clone
17A2 (See other available formats)
Regulatory Status
RUO
Other Names
T cell antigen receptor complex, T3
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
17A2_APCCyanine7_CD3_Antibody_031919_updated.png
C57BL/6 splenocytes were stained with CD45R/B220 FITC and CD3 (clone 17A2) APC/Cyanine7 (left) or Rat IgG2b, κ APC/Cyanine7 isotype control (right).
  • 17A2_APCCyanine7_CD3_Antibody_031919_updated.png
    C57BL/6 splenocytes were stained with CD45R/B220 FITC and CD3 (clone 17A2) APC/Cyanine7 (left) or Rat IgG2b, κ APC/Cyanine7 isotype control (right).
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Save
100221 25 µg ¥18,690
100222 100 µg ¥43,080
Description

CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
γδTCR-positive T-T hybridoma D1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.

Additional Product Notes

BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)
  1. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  2. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Wu Y, et al. 2021. Immunity. 54:2595. PubMed
  2. Martin-Martin I, et al. 2022. Cell Rep. 39:110648. PubMed
  3. Zhou H, et al. 2022. EMBO Rep. 23:e53791. PubMed
  4. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  5. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  6. Lee SH, et al. 2023. Nutrients. 15: . PubMed
  7. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  8. Meng S, et al. 2023. Stem Cell Investig. 10:2. PubMed
  9. Zhao M, et al. 2023. J Nanobiotechnology. 21:50. PubMed
  10. Abu Hejleh AP, et al. 2023. Int J Tryptophan Res. 16:11786469231153111. PubMed
  11. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  12. Mise Y, et al. 2022. Carcinogenesis. 43:647. PubMed
  13. Tao X, et al. 2022. J Exp Med. 219:. PubMed
  14. Mackel JJ, et al. 2022. Front Cell Infect Microbiol. 12:974175. PubMed
  15. Chung Y, et al. 2014. J Vis Exp. 89: 51660. PubMed
  16. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  17. Chen R, et al. 2022. J Mol Cell Biol. 14:. PubMed
  18. Jeon Y, et al. 2022. Cancers (Basel). 14:. PubMed
  19. Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed
  20. Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed
  21. Spitzer D, et al. 2023. Nat Protoc. 18:1510. PubMed
  22. Wang YC, et al. 2023. J Exp Med. 220:. PubMed
  23. Li G, et al. 2023. Cell Death Dis. 14:185. PubMed
  24. Cheng MI, et al. 2023. Nat Immunol. 24:780. PubMed
  25. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  26. Pelletier A, et al. 2023. EMBO Rep. 24:e56156. PubMed
  27. Tong L, et al. 2023. Sci Adv. 9:eade5041. PubMed
  28. Yazicioglu YF, et al. 2023. Nat Immunol. 24:991. PubMed
  29. Zhang J, et al. 2023. Theranostics. 13:2226. PubMed
  30. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  31. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  32. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  33. Israelow B, et al. 2020. bioRxiv. . PubMed
  34. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  35. Shimizu K, et al. 2020. Molecular Cell. 77(5):937-950.e6.. PubMed
  36. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  37. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  38. Marques RM, et al. 2021. Cell Death Differ. 28:3140. PubMed
  39. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  40. Chen S, et al. 2022. Cancer Discov. :. PubMed
  41. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  42. Durgeau A, et al. 2018. Nat Commun. 9:5097. PubMed
  43. Silver AC, et al. 2018. Heliyon. 4:e00579. PubMed
  44. Diao L, et al. 2022. iScience. 25:105511. PubMed
  45. Tirado-Gonzalez I, et al. 2021. Cancer Discov. 11:2924. PubMed
  46. Herman JD, et al. 2021. Nat Commun. 12:6853. PubMed
  47. Tilstam PV, et al. 2021. J Clin Invest. 131:. PubMed
  48. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  49. Leimkühler NB, et al. 2020. Cell Stem Cell. 28:637. PubMed
  50. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  51. Zhou Y, et al. 2016. Acta Pharmacol Sin. 10.1038/aps.2016.102. PubMed
  52. Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed
  53. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  54. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
  55. Inoue D, et al. 2021. Nat Genet. 53:707. PubMed
  56. Chung H, et al. 2021. Immune Netw. 21:e28. PubMed
  57. Mathews J, et al. 2014. PLoS One. 9:97707. PubMed
  58. Shi L, et al. 2021. Immunity. . PubMed
  59. Rafiq S, et al. 2018. Nat Biotechnol. 36:847. PubMed
  60. Super M, et al. 2021. Nat Biomed Eng. Online ahead of print. PubMed
  61. Wang Z, et al. 2020. Autophagy. 1:. PubMed
  62. Spees A, et al. 2014. Infect Immun . 82:1692. PubMed
  63. Yoshimi A, et al. 2019. Nature. 574:273. PubMed
  64. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  65. Han JP, et al. 2022. Sci Adv. 8:eabj6901. PubMed
  66. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
  67. Kunimoto H, et al. 2018. Cancer Cell. 33:44. PubMed
  68. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  69. Xue L, et al. 2021. BMC Cancer. 21:1134. PubMed
  70. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  71. Pandey V, et al. 2021. eLife. 0.416666666666667. PubMed
  72. Kleppe M et al. 2018. Cancer cell. 33(1):29-43 . PubMed
  73. Liu X, et al. 2022. Nat Cancer. :. PubMed
  74. Grune J, et al. 2022. Nat Cardiovasc Res. 1:649. PubMed
  75. Socodato R, et al. 2020. Sci Signal. 13: . PubMed
  76. Adane B, et al. 2019. Cell Rep. 27:238. PubMed
  77. Rashidi M, et al. 2019. J Immunol. 203:736. PubMed
  78. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  79. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  80. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  81. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  82. Rohner L, et al. 2020. Sci Rep. 0.570833333. PubMed
  83. Lang V, et al. 2021. Elife. 10:. PubMed
  84. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  85. Voss M, et al. 2015. Am J Physiol Lung Cell Mol Physiol. 309: L188 - L195. PubMed
  86. Fischer FA, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  87. Robles-Oteiza C, et al. 2021. Dis Model Mech. 14:. PubMed
  88. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  89. Jandke A, et al. 2020. Nat Commun. 3.075694444. PubMed
  90. Zhu W, et al. 2019. FASEB J. 33:5208. PubMed
  91. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  92. Kwok T, et al. 2022. Front Aging. 3:838943. PubMed
  93. Miyauchi E, et al. 2020. Nature. 585:102. PubMed
  94. Revathikumar P, et al. 2018. PLoS One. 13:e0193210. PubMed
  95. Dhar P, et al. 2021. Commun Biol. 4:905. PubMed
  96. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  97. Bellomo A, et al. 2020. Immunity. 53(1):127-142.e7. PubMed
  98. Teater M, et al. 2018. Nat Commun. 9:222. PubMed
  99. Draijer C, et al. 2018. Sci Rep. 8:5105. PubMed
  100. Yin S et al. 2019. Cancer cell. 35(2):283-296 . PubMed
  101. Sanchez HN, et al. 2020. Nat Commun. 0.5. PubMed
  102. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  103. Chen C, et al. 2020. Cell Rep. 2136:30. PubMed
  104. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  105. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  106. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  107. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  108. Rouse MD, et al. 2020. Front Microbiol. 11:414. PubMed
  109. Katzmarski N, et al. 2021. Nat Immunol. 22:1382. PubMed
  110. Jie Z, et al. 2014. J Immunol. 192:3289. PubMed
  111. Szodoray P, et al. 2021. Cell Reports. 36(6):109525. PubMed
  112. Dokoshi T, et al. 2020. Cell Rep. 30:61. PubMed
  113. Li C, et al. 2021. Chem Biol Drug Des. 97:1151. PubMed
  114. Sheng D, et al. 2022. J Immunother Cancer. 10:. PubMed
  115. Sharma R, et al. 2021. J Neuroinflammation. 72:18. PubMed
  116. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  117. Hildreth AD, et al. 2020. STAR Protoc. 1:100113. PubMed
  118. Wen J, et al. 2015. J Pharmacol Sci. 128: 116-124. PubMed
  119. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  120. Wang K, et al. 2021. Nat Commun. 12:4558. PubMed
  121. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  122. Kojima T, et al. 2016. Sci Rep. 6:36457. PubMed
  123. Nakazawa S, et al. 2020. Sci Rep. 10:14559. PubMed
RRID
AB_2057374 (BioLegend Cat. No. 100221)
AB_2242784 (BioLegend Cat. No. 100222)

Antigen Details

Structure
Ig superfamily, CD3/TCR, 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
Antigen recognition, TCR signal transduction, T cell activation
Ligand/Receptor
Peptide antigen/MHC-complex
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12502 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD3 Reagents Request Custom Conjugation
Description Clone Applications
FITC anti-mouse CD3 17A2 FC
PE anti-mouse CD3 17A2 FC
Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Alexa Fluor® 647 anti-mouse CD3 17A2 FC,IHC-F,3D IHC,SB
Alexa Fluor® 488 anti-mouse CD3 17A2 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse CD3 17A2 FC
Alexa Fluor® 700 anti-mouse CD3 17A2 FC
PerCP/Cyanine5.5 anti-mouse CD3 17A2 FC
PE/Cyanine7 anti-mouse CD3 17A2 FC
APC/Cyanine7 anti-mouse CD3 17A2 FC
Brilliant Violet 421™ anti-mouse CD3 17A2 FC,ICC
Brilliant Violet 570™ anti-mouse CD3 17A2 FC
Brilliant Violet 650™ anti-mouse CD3 17A2 FC
Brilliant Violet 785™ anti-mouse CD3 17A2 FC
Brilliant Violet 510™ anti-mouse CD3 17A2 FC
APC anti-mouse CD3 17A2 FC
Ultra-LEAF™ Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Brilliant Violet 605™ anti-mouse CD3 17A2 FC
Alexa Fluor® 594 anti-mouse CD3 17A2 IHC-F,FC,3D IHC,SB
Brilliant Violet 711™ anti-mouse CD3 17A2 FC
Biotin anti-mouse CD3 17A2 FC,IHC-F
PE/Dazzle™ 594 anti-mouse CD3 17A2 FC
APC/Fire™ 750 anti-mouse CD3 17A2 FC
Brilliant Violet 750™ anti-mouse CD3 17A2 FC
TotalSeq™-A0182 anti-mouse CD3 17A2 PG
TotalSeq™-B0182 anti-mouse CD3 17A2 PG
Spark Blue™ 550 anti-mouse CD3 17A2 FC
Spark NIR™ 685 anti-mouse CD3 17A2 FC
TotalSeq™-C0182 anti-mouse CD3 17A2 PG
APC/Fire™ 810 anti-mouse CD3 17A2 FC
PE/Fire™ 640 anti-mouse CD3 17A2 FC
Spark YG™ 570 anti-mouse CD3 17A2 IHC-F
PE/Fire™ 700 anti-mouse CD3 17A2 FC
PE/Cyanine5 anti-mouse CD3 17A2 FC
Spark Blue™ 574 anti-mouse CD3 Antibody 17A2 FC
Spark Violet™ 423 anti-mouse CD3 17A2 FC
PE/Fire™ 810 anti-mouse CD3 17A2 FC
Spark Red™ 718 anti-mouse CD3 17A2 FC
Spark UV™ 387 anti-mouse CD3 17A2 FC
Go To Top Version: 3    Revision Date: 03/19/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account